Search bioRxiv⌕ Search

Biology subjects

Green, Y. S.

Publications and source records attributed to Green, Y. S..

3 recordsLinked to original sources

Collagen Prolyl Hydroxylases Regulate HIF-α Levels Independently of pVHL in ccRCC

The hypoxia-inducible factors, HIF-1 and HIF-2, are master regulators of the hypoxia response. Under ambient conditions, both are hydroxylated by the HIF prolyl hydroxylases (HIF PHDs) resulting in ubiquitination by the pVHL E3 ligase complex, leading to subsequent proteasomal degradation. During hypoxia, the HIF PHDs are inhibited, resulting in HIF- stabilization and transcriptional activation of genes involved in the adaptation to hypoxia. Previous studies have shown that the collagen PHD, P4HA1, which promotes proline hydroxylation of collagen, inhibits the HIF PHDs by modulating levels of -ketoglutarate and succinate, thus enhancing HIF-1 stability by preventing pVHL-mediate degradation. Here, we investigate the role of collagen PHDs in the regulation of HIF-1/2 in the setting of pVHL deficiency in ccRCC. We show that the collagen PHDs P4HA1 and P4HA2 are required for HIF-1 translation and HIF-2 transcription and translation independently of pVHL function, through a mechanism regulated in part by P4HA1/2-driven collagen production. Thus, we reveal a novel pVHL-independent mechanism of HIF-1/2 regulation driven by P4HA1/2 in ccRCC. Since the HIFs have been strongly implicated in ccRCC initiation and progression, our data suggests that inhibition of P4HA1/2 may be a promising therapeutic strategy in ccRCC.

cancer biology↗

HNF4α controls growth, identity and response to KRAS inhibition of invasive mucinous adenocarcinoma of the lung

Cellular plasticity is a hallmark of cancer, enabling tumor cells to alter identity and evade therapeutic pressure. In invasive mucinous adenocarcinoma of the lung (IMA), NKX2-1 loss triggers a pulmonary to gastric switch marked by aberrant activation of HNF4, a master regulator of gastrointestinal/hepatic differentiation. We find that HNF4 promotes IMA growth and activates a gastric pit cell-like program. Hnf4a deletion induces IMA dedifferentiation, enabling FoxA1/2 to access de novo sites and activate alternative identities. HNF4 also induces a mucinous program associated with tolerance to KRAS blockade, and HNF4 loss enhances response to KRASG12D inhibition. Mechanistically, HNF4 blocks cell cycle exit in drug-tolerant persister cells and promotes activity of the antioxidant transcription factor NRF2. NRF2 activation partially rescues effects of Hnf4a deletion on KRASG12D inhibition, whereas NRF2 inhibition enhances sensitivity to KRASG12D blockade. Thus, HNF4 is a key regulator of identity and primary response to KRASG12D inhibition in IMA. SIGNIFICANCEIMA is a genetically and epigenetically distinct LUAD subtype for which targeted therapies are lacking due to the high proportion of KRAS mutations. This study points to blockade of the HNF4 -> NRF2 axis as a potential strategy to enhance primary response to KRAS inhibition in IMA.

cancer biology↗

HAF Prevents Hepatocyte Apoptosis and Hepatocellular Carcinoma through Transcriptional Regulation of the NF-κB pathway.

BackgroundHepatocellular carcinoma (HCC) incidence is increasing worldwide due to the obesity epidemic, which drives metabolic dysfunction-associated steatohepatitis (MASH) that can lead to HCC. However, the molecular pathways that lead to MASH-HCC are poorly understood. We have previously reported that male mice with global haploinsufficiency of hypoxia-associated factor, HAF (SART1+/-) spontaneously develop MASH/HCC. However, the cell type(s) responsible for HCC associated with HAF loss are unclear. ResultsSART1-floxed mice were crossed with mice expressing Cre-recombinase within hepatocytes (Alb-Cre; hepS-/-) or macrophages (LysM-Cre, macS-/-). Only hepS-/- mice (both male and female) developed HCC suggesting that HAF protects against HCC primarily within hepatocytes. HAF-deficient macrophages showed decreased P-p65 and P-p50 and in many major components of the NF-{kappa}B pathway, which was recapitulated using HAF siRNA in vitro. HAF depletion increased apoptosis both in vitro and in vivo, suggesting that HAF mediates a tumor suppressor role by suppressing hepatocyte apoptosis. We show that HAF regulates NF-{kappa}B activity by controlling transcription of TRADD and RIPK1. Mice fed a high-fat diet (HFD) showed marked suppression of HAF, P-p65 and TRADD within their livers after 26 weeks, but manifest profound upregulation of HAF, P-65 and TRADD within their livers after 40 weeks of HFD, implicating deregulation of the HAF-NF-{kappa}B axis in the progression to MASH. In humans, HAF was significantly decreased in livers with simple steatosis but significantly increased in HCC compared to normal liver. ConclusionsHAF is novel transcriptional regulator of the NF-{kappa}B pathway that protects against hepatocyte apoptosis and is a key determinant of cell fate during progression to MASH and MASH-HCC.

cancer biology↗